Reuters logo
3 个月内
BRIEF-AMAG Pharmaceuticals says positive topline data from Feraheme label expansion study
2017年5月2日 / 上午11点18分 / 3 个月内

BRIEF-AMAG Pharmaceuticals says positive topline data from Feraheme label expansion study

1 分钟阅读

May 2 (Reuters) - AMAG Pharmaceuticals Inc

* Announces positive topline data from phase 3 feraheme® (ferumoxytol) label expansion study

* Achieved all primary and secondary safety and efficacy endpoints

* On track to file SNDA mid-year with a potential approval and launch in first half of 2018

* Expects to file a supplemental nda with u.s. Fda by mid-2017 to potentially broaden use of feraheme Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below